follicular lymphoma

(redirected from Follicular non-Hodgkin's lymphoma)
Also found in: Medical, Acronyms.

follicular lymphoma

[fə′lik·yə·lər lim′fō·mə]
(medicine)
A premalignant lymphoma in which the lymph nodes show enlarged follicles composed predominantly of closely packed, large reticuloendothelial cells.
References in periodicals archive ?
The primary investigators of the study concluded that Zevalin consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma is highly effective, resulting in a total complete response (CR + CRu) rate of 87 percent and prolongation of median progression-free survival (PFS) by approximately two years, with a toxicity profile comparable to that seen with Zevalin's use in approved indications.
Genmab A/S (OMX: GEN) announced today it has amended the design of an ongoing pivotal study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL) to a single arm trial that will now include approximately 81 patients.
The sBLA will propose a label expansion to include use of the Zevalin(R) therapeutic regimen ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma.
COPENHAGEN, September 22 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma (NHL) patients in the Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).
The new trials include the following disease indications: follicular Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Metastatic Sarcoma, Chronic Myelogenous Leukemia, and Non-Small Cell Lung Cancer (NSCLC).
Food and Drug Administration (FDA) in September to discuss the possibility of filing a supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma.
Santos, Biovest's Senior Vice President, Scientific Affairs, Product Development & Regulatory Affairs, will present an overview of BiovaxID[R], a late-stage personalized cancer vaccine developed in collaboration with the National Cancer Institute for the treatment of follicular non-Hodgkin's lymphoma and other B-cell lymphomas.
Zevalin is approved for relapsed follicular non-Hodgkin's lymphoma based on superior overall and complete response rates compared to rituximab, including rituximab-refractory follicular non-Hodgkin's lymphoma where Zevalin resulted in a 74 percent overall response rate with 15 percent complete and unconfirmed complete responses," said James A.
Santos, Biovest's Vice President, Scientific Affairs, Product Development & Regulatory Affairs, will present an overview of BiovaxID[R], a late-stage personalized cancer vaccine developed in collaboration with the National Cancer Institute for the treatment of follicular non-Hodgkin's lymphoma and other B-cell lymphomas.
COPENHAGEN, September 27 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has amended the design of an ongoing pivotal study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL) to a single arm trial that will now include approximately 81 patients.
2 months, patients with previously untreated follicular non-Hodgkin's lymphoma treated with a standard, single-dose infusion of ZEVALIN as part of the ZEVALIN Therapeutic Regimen after partial or complete response to first-line chemotherapy had a nearly three-year advantage in median progression-free survival (PFS) compared to patients treated with either chemotherapy alone or chemotherapy plus rituximab (49 months versus 14 months).
New York University Cancer Institute * Merril Hoge, Patient With Follicular Non-Hodgkin's Lymphoma, ESPN Analyst And Former Pittsburgh Steeler